Taking IQCODE as an exemplar, in the original validated versions of the scale, it asks a series of questions about how cognition and functioning have changed >10-year period. Individual item scores are collated to give a summary score. Various IQCODE cut-offs have been described to determine clinically important cognitive decline. 7,8 Some have suggested that a high threshold, for example IQCODE >3.6, should be used to determine dementia, whereas a more inclusive threshold should be chosen to define any cognitive impairment. This
I
nternational guidelines recommend that we assess all stroke survivors for cognitive disorders, however, there is no consensus on the optimal method of assessment. 1, 2 A usual first step is to assess with a direct cognitive screening tool. These tools have use but diagnostic accuracy is imperfect. 3 In the context of stroke, completion and assessment of such tools is complicated by stroke-related impairments and physical illness. 4, 5 An alternative or complementary approach is to seek a history suggestive of cognitive problems from family or caregivers. 6 Using collateral information sources to describe medium to longer term cognitive change is particularly attractive for stroke settings because the informant view should be less subject to variation from stroke-related impairments; should not be biased by educational level or cultural factors and offers potential for describing prestroke cognition in the acute phase of stroke. 7 Informant assessment can be operationalized using a validated questionnaire, such as the Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE).
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approach has been used in several important stroke cognition epidemiological studies. [9] [10] [11] Other informant assessments include the 8-item interview to differentiate aging from dementia . 12 This short questionnaire seems to have favorable properties compared with IQCODE. 13 The Blessed Dementia Scale (BDS) is a multidomain informant assessment that describes change in functional ability, activities of daily living, and personality.
14 Some assessments include an informant component. For example, the GP-Cog is a screening test designed for use in primary care, comprising a direct to patient assessment complemented by 6 informant questions. 15 None of these informant-based tests have been specifically designed for use in stroke.
Informant-based assessments can be used for 3 broad purposes in stroke care: (1) tools can be used to assess for prestroke cognitive decline; (2) tools can be used to assist in the process of diagnosing poststroke cognitive impairment; and (3) tools can be used as a prognostic aid, identifying a period of cognitive decline that may predict future dementia. In situation (3), the IQCODE is being used to detect early cognitive change that is not sufficient to warrant a label of dementia but that may predict risk of future dementia states ( Figure 1 ).
We sought to collate the published evidence describing test properties of informant-based cognitive assessments when used in stroke settings.
Methods
We performed a systematic review after best practice guidance in conduct and reporting. 16, 17 All aspects of searching, data extraction, and quality assessment were performed by 2 independent researchers (A.M. and N.M.) with access to a third arbitrator (T.Q.) as needed. We created a protocol describing the search strategy and registered this with the PROSPERO database:PROSPERO 2014:CRD42014014554 (http://www.crd.york.ac.uk/PROSPERO/ display_record.asp?ID=CRD42014014554).
Our primary aim was to describe the accuracy of informant-based questionnaires for diagnosis of dementia or multidomain cognitive impairment in stroke survivors.
Our index test was any standardized informant-based cognitive screening assessment. We did not specify how the assessment was performed. We prespecified subgroup analyses based on possible uses of informant assessment: (1) informant assessment (usually performed in the acute stroke period) for prestroke cognitive issues; (2) informant assessment for contemporaneous assessment of poststroke dementia; and (3) informant assessment (usually performed in the acute period) for predicting future cognitive issues (delayed verification). 18 Our target condition was dementia or multidomain cognitive impairment. This broad classification recognises that a diagnosis of clinically important cognitive issues can be made without necessarily assigning a dementia label. We accepted clinical diagnosis of dementia made using any recognized classification system and accepted a diagnosis of cognitive impairment based on multidomain neuropsychological assessment.
Our population of interest was stroke survivors. We operated no exclusions based on time since stroke or healthcare setting. In studies with mixed populations, we included those with >70% stroke survivors.
We developed search terms using a concept-based approach, combined with a validated stroke filter. We used Medical Subject Headings and other controlled vocabulary. We included search terms relating to commonly used informant-based cognitive assessments (IQCODE, AD-8, GP-Cog, and BDS) as well as generic terms relating to cognitive testing. We searched across multiple, cross-disciplinary electronic databases from inception to April 2015. A collaborator (Y.F.) performed a focused search of Chinese literature databases. We had searched conference proceedings from international stroke meetings. Full search strategy was detailed in Table I in the online-only Data Supplement.
We screened all titles generated by initial searches for relevance. Abstracts were assessed and potentially eligible studies were reviewed as full manuscripts against inclusion criteria. We checked reference lists of relevant studies and reviews for further titles, repeating the process until no new titles were found.
We extracted data to a study specific proforma. For informant scales with various cut points, we extracted data for all thresholds available, for studies with assessment at varying times poststroke we extracted data for each time point. We created tables describing characteristics of included studies, characteristics of informant assessments used, and characteristics of patients included. Where possible, for test accuracy data, we constructed 2 by 2 contingency tables to allow calculation of sensitivity, specificity, and predictive values against a dichotomous outcome of cognitive impairment/no cognitive impairment. Where data were not immediately accessible for the paper, we contacted lead authors.
Where data allowed, we calculated sensitivity, specificity, and corresponding 95% confidence intervals (95% CI) on test accuracy forest plots (RevMan 5.1, Cochrane Collaboration) and pooled test accuracy data using the bivariate approach with a bespoke macro. 19 We did not formally assess publication bias, as standard tests such as funnel plots are not appropriate and there is no consensus on the optimal measure of such bias in test accuracy review.
We assessed risk of bias and generalizability using the Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2) 20 tool. QUADAS-2 assesses domains of patient selection, application of index test, application of reference standard, and patient flow/timing. We previously created and validated a series of anchoring statements for QUADAS-2 for test accuracy work with a dementia reference standard. 21 We assessed quality of reporting using the dementia-specific extension to the Standards for Reporting of Diagnostic Accuracy STARDdem 16 tool. STARDdem assesses reporting of key items for dementia test accuracy work across the introduction, methods, results, and discussion sections of a manuscript. Full details of scoring criteria are given in the online-only Data Supplement.
Results
After deduplication, we screened 1432 titles (Figure 2 ). After assessment of abstract or full paper, we included 11 studies in our review. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Ten studies detailed the IQCODE, including n=1994 participants (n=465 [23%] with dementia). [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] One There was substantial study heterogeneity. Across the included studies, informant assessments were used for a variety of purposes across various settings, with varying cut points ( Table 1; Table II in the online-only Data Supplement). The reporting around application of IQCODE was poor for several studies and it was not clear if a validated form of the questionnaire was used (n=3 studies); the time period over which IQCODE retrospective review was performed (n=4 studies) or which informants were used (n=3 studies; Table III in the online-only Data Supplement). The generalizability of the patient populations used to assess IQCODE was variable. Where data were reported there were substantial baseline exclusions and included patient were young with relatively mild stroke (Table II in the online-only Data Supplement).
Prestroke Dementia
No study described test properties of assessments for the diagnosis of prestroke cognitive decline versus a reference standard for clinical diagnosis (Table 1) .
Contemporaneous Diagnosis of Poststroke Dementia
For IQCODE (4 papers, n=1197 participants), [23] [24] [25] [26] summary test metrics were sensitivity: 0.81 (95% CI, 0.60-0.93; range, 0.33-0.88) and specificity: 0.82 (95% CI, 0.64-0.92; range, 0.63-0.98; Figure 3 ; Table 2 ).
The BDS had sensitivity 60% and specificity 76% (positive predictive value: 0.73; negative predictive value: 0.64) for diagnosis of any memory-related impairment.
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Delayed Verification/Prognosis
For IQCODE (5 papers, n=837 participants), [26] [27] [28] [29] [30] summary test metrics were sensitivity: 0.60 (95% CI, 0.32-0.83; range, 0.25-0.93) and specificity: 0.97 (95% CI, 0.70-1.00; range, 0.66-1.00; Figure 3 ; Table 2 ). Where the approach to analysis was described, most papers assessed cognitive decline in the immediate period poststroke and described the association with longer term dementia diagnosis ( Figure I in the onlineonly Data Supplement).
No papers scored low risk of bias on all QUADAS-2 items. Areas of concern were around patient flow/loss to follow-up (with substantial loss of IQCODE data, where reported) and the application of the IQCODE (risk of incorporation bias and using IQCODE in a nonvalidated way; Figure 4 ; Table IV in the online-only Data Supplement). There were issues with reporting; no papers reported all details as recommended in STARDdem, particular problems were around reporting of results and details of statistical analyses. For example, only 2 papers described blinding between those applying the informant test and those performing clinical assessment; 1 paper described how missing or indeterminate results were handled and no papers described test reliability or reproducibility (Table V and Figure II in the online-only Data Supplement).
Discussion
Although there are many informant-based cognitive assessment tools available, 6 few have been validated in stroke. Only the IQCODE had >1 paper describing stroke test properties and there was substantial heterogeneity in test accuracy reported. Across the included studies, there were issues with study quality and reporting and we need to be cautious in the interpretation of these data. 
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Accepting these caveats, we can draw some conclusions on properties of IQCODE in stroke. Across all studies, IQCODE showed a pattern of specificity but high false negative rate. IQCODE for assessing poststroke dementia had reasonable test accuracy. In practice, IQCODE or similar would often be used along with another direct to patient cognitive test; however, we found no studies validating this approach.
IQCODE early after stroke has been used as a tool to predict future dementia. We accept that the use of retrospective assessment to predict future dementia is counter intuitive, and it is interesting that a number of papers used this approach. When used for this purpose, a positive IQCODE is likely to be associated with dementia but many that develop dementia will have an initial IQCODE assessment below the threshold set for this purpose (specific but lacks sensitivity). This pattern of trade-off between sensitivity and specify changed when IQCODE was used at longer periods after the stroke event. The interpretation of these data is complicated by limited reporting around how the IQCODE was applied and this was apparent in our assessments of quality and reporting.
Informant assessments such as IQCODE are often used in practice and in research to assess prestroke cognition. There are many excellent examples of describing prestroke cognition using IQCODE. 33, 34 Although this approach makes intuitive sense, we found no published reports that validate the test accuracy of this use of IQCODE.
Our data adds to the literature on test properties of brief cognitive assessments in stroke. The accuracy of IQCODE for diagnosis of poststroke dementia was similar to summary metrics for other direct to patient cognitive assessments in stroke. 1 There is no ideal cognitive test for the use with stroke populations. Choice of test needs to consider accuracy but also the purpose of the testing and issues such as feasibility. 35 Although based on a self-completion questionnaire, we should not assume feasibility and acceptability of IQCODE. We note the high noncompletion rates of IQCODE in many of these studies, reminding us that IQCODE requires a suitable informant and that the informant has to understand and complete the questionnaire. There are some data in nonstroke settings to suggest that availability of an informant when accessing health care is associated with abnormal cognition. 36 IQCODE and other informant assessments may be complicated where a spouse or caregiver also has cognitive issues. In some centres, informants have a brief cognitive screen to assess their suitability to complete questionnaires, such as IQCODE. It is unfortunate that no assessment of informants was made in any of the articles included in this review.
Interpreting our data on IQCODE, we should remember that IQCODE was developed for assessing dementia in community dwelling older adults and there are many reasons why the questionnaire may not work well in stroke. Certain IQCODE items may be difficult to score in the context of stroke, for example the IQCODE question on using gadgets may give false positives for stroke survivors with physical disability but no cognitive deficit. The memory-based focus of IQCODE may be less appropriate in vascular cognitive impairment syndromes, where executive function deficits may predominate. Finally, early physical recovery that can occur after stroke may be wrongly scored as positive cognitive change on IQCODE, a situation that would not be seen in Alzheimer disease.
A particular issue in our quality assessment was around the application of the IQCODE. An issue with IQCODE is that it may be used in practice to inform the diagnostic formulation. There were included papers that risked such incorporation It is interesting to note how the use of IQCODE in stroke deviates from that described in the original IQCODE derivation and validation work. The original IQCODE was designed to describe cognitive decline >10-year period. This approach is better suited to assess a progressive neurodegenerative condition such as Alzheimer disease, rather than an acute event, such as stroke. In practice, assessors may use the IQCODE questions to explore cognitive change since a stroke event, which may not necessarily be 10 years past. Some papers also use repeated IQCODE assessments at end points. Altering the IQCODE in this way is not validated and so many papers were scored as potential risk of bias/ poor external validity because of this issue. Where IQCODE covers a 10-year period that includes a stroke event, the IQCODE result gives information on general cognitive decline but does not tell us that this decline relates purely to stroke. These concerns should not dissuade clinicians and researchers from using informant-based assessments but suggest that more work is needed around tailoring informant assessments to fit poststroke populations. The data from our review do not allow us to give definitive guidance on when IQCODE should be applied. To avoid recall biases, we would suggest that informant assessment for prestroke dementia be performed close to the stroke event but with sufficient time to allow the informant to adjust to the diagnosis of stroke in their relative or friend.
Strengths of our study were the comprehensive literature search, including access to non-English language electronic databases. We acknowledge the between study heterogeneity and issues with risk of bias, generalizability and reporting. To allow for data synthesis, we accepted any clinical diagnosis of a cognitive syndrome as our reference standard. As a result of this, the summary estimates we offer are illustrative and should not be interpreted as definitive test accuracy metrics. Number of included papers was too small to allow meaningful sensitivity analyses around these issues.
Our data do not allow us to make a definitive statement on the best available informant assessment. Although there Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) thresholds are given as presented in primary paper (some are average score and some are raw score); where >1 IQCODE threshold employed, the primary cutpoint is described. PPV/NPV indicates positive/negative predictive value; sens, sensitivity; and spec, specificity.
*Data from extended abstract and parent studies. Table I .
Detailed summary of search strategy
We created sensitive search terms based on concepts of "informant assessment" and "dementia/cognition" with a validated "stroke" filter.
We searched multiple cross-disciplinary, international electronic databases. Were all patients included in the analysis?
ALOIS (Cochrane Dementia and
Risk of bias:
High/low/ unclear We provide some core anchoring statements for quality assessment of diagnostic test accuracy reviews of IQCODE in dementia. These statements are designed for use with the QUADAS-2 tool and were derived during a two-day, multidisciplinary focus group.
During the focus group and the piloting/validation of this guidance, it was clear that certain issues were key to assessing quality, while other issues were important to record but less important for assessing overall quality. To assist, we describe a system wherein certain items can dominate. For these dominant items, if scored "high risk" then that section of the QUADAS-2 results table is likely to be scored as high risk of bias regardless of other scores. For example, in dementia diagnostic test accuracy studies, ensuring that clinicians performing dementia assessment are blinded to results of index test is fundamental. If this blinding was not present then the item on reference standard should be scored "high risk of bias", regardless of the other contributory elements.
We have detailed how QUADAS-2 has been operationalised for use with dementia reference standard studies below. In these descriptors dominant items are labelled as "high risk of bias for total section regardless of other items".
In assessing individual items, the score of unclear should only be given if there is genuine uncertainty. In these situations review authors will contact the relevant study teams for additional information.
Anchoring statements to assist with assessment for risk of bias
Selection
Was a case-control or similar design avoided?
Designs similar to case-control that may introduce bias are those designs where the study team deliberately increase or decrease the proportion with the target condition. For example, a population study may be enriched with extra dementia patients from a secondary care setting. Such studies will be automatically labelled high risk of bias and this will be assessed as a potential source of heterogeneity.
If case-control used then grading will be high risk of bias for total section regardless of other items (in fact case-control studies will not be included in this review)
Was the sampling method appropriate?
Where sampling is used, the designs least likely to cause bias are consecutive sampling or random sampling. Sampling that is based on volunteers or selecting participants from a clinic or research resource is prone to bias.
Are exclusion criteria described and appropriate?
The study will be automatically graded as unclear if exclusions are not detailed (pending contact with study authors). Where exclusions are detailed, the study will be graded as low risk of bias if exclusions are felt to be appropriate by the review authors. Certain exclusions common to many studies of dementia are: medical instability; terminal disease; alcohol/substance misuse; concomitant psychiatric diagnosis; other neurodegenerative condition.
Post hoc exclusions will be labelled high risk of bias for total section regardless of other items.
Index Test
Was IQCODE assessment performed without knowledge of clinical dementia diagnosis?
Terms such as "blinded" or "independently and without knowledge of" are sufficient and full details of the blinding procedure are not required. This item may be scored as low risk of bias if explicitly described or if there is a clear temporal pattern to order of testing that precludes the need for formal blinding i.e. all IQCODE assessments performed before dementia assessment.
If there is no attempt at blinding grading will be high risk of bias for total section regardless of other items.
Were IQCODE thresholds prespecified?
For scales there is often a reference point (in units or categories) above which participants are classified as "test positive"; this may be referred to as threshold; clinical cut-off or dichotomisation point. A study is classified high risk of bias if the authors define the optimal cut-off post-hoc based on their own study data. Certain papers may use an alternative methodology for analysis that does not use thresholds and these papers should be classified as low risk of bias.
Were sufficient data on IQCODE application given for the test to be repeated in an independent study? Particular points of interest for IQCODE include method of administration (for example, self-completed questionnaire versus direct questioning interview); nature of informant; language of assessment. If a novel form of IQCODE is used, details of the scale should be included or a reference given to an appropriate descriptive text. Where IQCODE is used in a novel manner, for example, a translated questionnaire, there should be evidence of validation work. Authors should report the timing of the analysis plan with respect to data collection:
was the analysis plan set out in a protocol before index and reference standards were performed? If not, when was the analysis plan created? how the criteria were applied (e.g. by individual clinicians, by consensus conference, by semi-automated algorithm).
Imaging and laboratory tests: specify materials and instruments, including sample handling and concordance with any harmonisation criteria. In new assays describe all steps in detail. Any particular preparation of participants should be described. Report inter-and intra-rater agreement.
Reference or describe the content of training materials used.
Reference or describe details of lab certification and harmonised biomarker assays. The training which image readers receive should be carefully described. Studies in which the accuracy of 'majority' judgements are reported should also report data for the minority judgements. Reports of the impact of training should clearly describe the characteristics of the sample used for training and whether it is representative of the group to which the test will be applied.
Results
Participants:
When study was performed, including beginning and end dates of recruitment Pertinent particularly to longitudinal (delayed verification) studies, authors should report recruitment dates of the study (not to be confused with recruitment dates of the wider cohort study from which it might be drawn), and the beginning (first participant) and end (last participant) dates of the periods during which index test/s and reference standard were performed.
Report the period for the index test and period for the reference standard separately if it is not clear. Test results:
Time-interval between the index tests and the reference standard, and any treatment administered in between Specify the follow-up period for all subjects in relation to their outcomes. It should be specified whether or not participants had received any treatments which might affect disease progression. Estimates: 
Discussion
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Discuss the clinical applicability of the study findings Discuss differences in age and comorbidity between the study population and the patients typically seen in clinical practice.
Discuss whether the reported data demonstrate 'added' or 'incremental' value of the index test over and above other routine diagnostic tests.
Identify stage of development of the test (e.g. proof of concept; defining accuracy in a typical spectrum of patients);
Discuss the further research needed to be done to make test applicable to population in whom likely to be applied in practice. 
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